Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.
Saved in:
| Title: | Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial. |
|---|---|
| Authors: | Christine CW; (San Francisco)., Richardson RM; (Cambridge, MA)., Van Laar A; (Chapel Hill, NC)., Fine EM; (Waltham, MA)., Khwaja OS; (Basel, Switzerland)., Liang GS; (San Diego)., Bankiewicz K; (San Francisco)., Larson PS; (Tucson). |
| Source: | Neurology [Neurology] 2022 Aug 09; Vol. 99 (6), pp. 260-261. |
| Publication Type: | Journal Article; Comment |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Print Cited Medium: Internet ISSN: 1526-632X (Electronic) Linking ISSN: 00283878 NLM ISO Abbreviation: Neurology Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
